Article Text

Download PDFPDF

PO.3.70 Case report of a systemic lupus erythematosus patient with an ulcerative necrotic vasculitis: features of therapeutic approaches
  1. A Shumilova1,
  2. E Naryshkin1,
  3. E Stolyarevich2 and
  4. T Reshetnyak1
  1. 1V.A.Nasonova Research Institute of Rheumatology ~ Moscow ~ Russian Federation
  2. 2City Clinical Hospital No. 52 of the Moscow Department of Health ~ Moscow ~ Russian Federation


Background Systemic lupus erythematosus (SLE) is a heterogeneous chronic rheumatic autoimmune disease with a range of clinical manifestations, characterized by impaired activation of cellular and humoral links of immunity, uncontrolled hyperproduction of autoantibodies of a wide spectrum to nuclear antigens and the formation of immune complexes that cause immuno-inflammatory damage to tissues and organs. Vasculitis in connective tissue disease (CTD) is quite rare, it is reported in approximately 10% of patients with CTD, SLE shows the highest association rate.

Purpose To report a case of a patient with SLE with ulcerative necrotic vasculitis of the upper and lower extremities with the formation of dry necrosis in combination with lupus nephritis (LN).

Methods A 26-year-old female patient with SLE for 1 year was diagnosed based on ulcerative necrotic vasculitis of the upper and lower extremities with the formation of dry necrosis, Class V LN (proteinuria, erythrocyturia, cylindruria), adhesive pericarditis, immunological disorders (highly positive antibodies to Sm+, anti-Ro/SS-A+), ANF hep-2 positivity.

Results An anamnesis of the disease, physical, laboratory and instrumental examination and treatment tactics are presented in table 1.

Abstract PO.3.70 Table 1

Clinical and laboratory manifestations of the disease and treatment tactics

Conclusions Necrotizing vasculitis is always secondary to SLE and it is necessary to exclude antiphospholipid syndrome. Vessels of any size may be involved, but mainly medium vessels vasculitis in SLE is reported. The most common clinical manifestations are ischemic lesion, ulcers, gangrene etc. It may be an early warning sign for systemic involvement. The combination of glucocorticoids, hydroxychloroquine, cytostatic (azathioprine), anti-B-cell therapy (rituximab) is highly effective. No recurrence of vasculitis was detected within 7 months after correction of therapy.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.